MedTrace Logo

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-06-05

No results posted yet for this study

Summary

The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Conditions

Interventions

DRUG

Trametinib

Trametinib will be administered orally once daily via tablet.

DRUG

Ruxolitinib

Ruxolitinib will be administered orally twice daily (BID) via tablet.

DRUG

Retifanlimab

Retifanlimab will be administered intravenously (IV) on Day 8 of a 28-day cycle..

Sponsors & Collaborators

Principal Investigators

  • Peter Hosein, MD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-19
Primary Completion
2025-05-30
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05440942 on ClinicalTrials.gov